MAYNE PHARMA GROUP LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.17 AUD | -7.36% |
|
-13.38% | +0.57% |
| May. 10 | Mayne Pharma Group's Nextstellis Oral Contraceptive Receives Two Additional US Patents | MT |
| Feb. 26 | Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 384M 255M | Sales 2025 * | 429M 285M | Capitalization | 540M 359M |
|---|---|---|---|---|---|
| Net income 2024 * | -83M -55.15M | Net income 2025 * | -2M -1.33M | EV / Sales 2024 * | 1.22 x |
| Net cash position 2024 * | 72.1M 47.9M | Net cash position 2025 * | 60.91M 40.47M | EV / Sales 2025 * | 1.12 x |
| P/E ratio 2024 * |
-6.51
x | P/E ratio 2025 * |
-194
x | Employees | 967 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.67% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mayne Pharma Group Limited
More press releases
| 1 day | -7.13% | ||
| 1 week | -13.38% | ||
| Current month | -11.26% | ||
| 1 month | -11.14% | ||
| 3 months | +16.26% | ||
| 6 months | +42.84% | ||
| Current year | +0.57% |
1 week
6.17
7.21
1 month
6.177.46
Current year
5.007.46
1 year
2.757.46
3 years
0.228.50
5 years
0.2212.90
10 years
0.2242.20
| Managers | Title | Age | Since |
|---|---|---|---|
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
Aaron Gray
DFI | Director of Finance/CFO | - | 22-08-28 |
Keith Moore
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Frank Condella
CHM | Chairman | 70 | 18-05-29 |
Patrick Blake
BRD | Director/Board Member | 59 | 18-06-27 |
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 6.17 | -7.36% | 176 089 |
| 24-05-14 | 6.66 | -5.80% | 759,072 |
| 24-05-13 | 7.07 | +0.86% | 72,172 |
| 24-05-10 | 7.01 | -1.54% | 85,754 |
| 24-05-09 | 7.12 | -0.28% | 159,902 |
Delayed Quote Australian S.E., May 15, 2024 at 12:43 am EDT
More quotes
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Companyâs segments include Womenâs Health, Dermatology, and International. The Womenâs Health segment distributes womenâs health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.66
AUD
Average target price
7.035
AUD
Spread / Average Target
+5.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.57% | 358M | |
| +21.21% | 44.4B | |
| +24.39% | 23.03B | |
| +18.00% | 15.14B | |
| +13.68% | 13.12B | |
| +44.81% | 11.85B | |
| -7.85% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.22% | 5.52B |
- Stock Market
- Equities
- MYX Stock